Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus PYRIDOSTIGMINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus PYRIDOSTIGMINE BROMIDE.
ARICEPT vs PYRIDOSTIGMINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Reversible acetylcholinesterase inhibitor, prolonging the action of acetylcholine at nicotinic and muscarinic receptors.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
Oral: 60-120 mg every 3-4 hours (max 360 mg/day). Intravenous: 0.1-0.25 mg/kg IV (max 10 mg per dose) for reversal of nondepolarizing neuromuscular blockade, given with glycopyrrolate or atropine. Intramuscular: 0.2-1 mg for postoperative urinary retention.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal half-life: 1-2 hours (prolonged in renal impairment; up to 6 hours in anuria)
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Renal: 70-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor